Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.
Abstract Purpose The Society for Integrative Oncology (SIO) produced an evidence-based guideline on use of integrative therapies during and after breast cancer treatment that was determined to be relevant to the American Society of Clinical Oncology (ASCO) membership. ASCO considered the guideline for endorsement. Methods The SIO guideline addressed the use of integrative therapies for the management of symptoms and adverse effects, such as anxiety and stress, mood disorders, fatigue, quality of life, chemotherapy-induced nausea and vomiting, lymphedema, chemotherapy-induced peripheral neuropathy, pain, and sleep ...
Source: Clinical Genitourinary Cancer - June 11, 2018 Category: Cancer & Oncology Authors: Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE, Fouladbakhsh JM, Gil B, Hershman DL, Mansfield S, Mussallem DM, Mustian KM, Price E, Rafte S, Cohen L Tags: J Clin Oncol Source Type: research

Hormone Therapy: Key Points From NAMS 2017 Position Statement.
Abstract The goal of the 2017 North American Menopause Society Hormone Therapy (HT) Position Statement is to remove fear about HT and encourage individualized shared decision making, using best available evidence. Systemic HT is safe and effective for symptomatic menopausal women aged younger than 60 years and within 10 years of menopause. Special populations of early menopause, high risk for fracture, risk of breast or uterine cancer, and extended duration are discussed. With longer duration of use, periodic evaluation and reassessment of health risks are needed. Lowered doses, transdermal therapies or newer opti...
Source: Clinical Genitourinary Cancer - June 8, 2018 Category: Cancer & Oncology Authors: Pinkerton JV Tags: Clin Obstet Gynecol Source Type: research

Updates in the Evaluation and Management of Breast Cancer.
This article provides an overview of the management of noninvasive and invasive breast cancer, which is often complex and varies according to patient factors, disease stage, and breast cancer subtype. Although much progress has been made, continued research endeavors are ongoing; enrollment of eligible patients in prospective clinical trials is an essential way to improve patient outcomes. PMID: 29866283 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - June 1, 2018 Category: Cancer & Oncology Authors: O'Sullivan CC, Loprinzi CL, Haddad TC Tags: Mayo Clin Proc Source Type: research

AllergoOncology: Generating a canine anti-cancer IgE against the epidermal growth factor receptor (EGFR).
Abstract Anti-cancer immunotherapies currently rely on IgG antibodies. In line with the AllergoOncology concept we provide evidence that tumor-specific IgE, alone or combined with IgG, may be superior to IgG treatment alone. The novel can225IgE-λ was made for future studies in dogs as translational model patients. PMID: 29746883 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - May 7, 2018 Category: Cancer & Oncology Authors: Fazekas-Singer J, Singer J, Ilieva KM, Matz M, Herrmann I, Spillner E, Karagiannis SN, Jensen-Jarolim E Tags: J Allergy Clin Immunol Source Type: research

The 21-gene Recurrence Score ® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial). BMC Cancer. 2018 May 04;18(1):526 Authors: Penault-Llorca F, Filleron T, Asselain B, Baehner FL, Fumoleau P, Lacroix-Triki M, Anderson JM, Yoshizawa C, Cherbavaz DB, Shak S, Roca L, Sagan C, Lemonnier J, Martin AL, Roché H Abstract BACKGROUND: The 21-gene Recurrence Score (RS) result predicts outcome and chemotherapy benefit in node-negative ...
Source: Clinical Genitourinary Cancer - May 4, 2018 Category: Cancer & Oncology Authors: Penault-Llorca F, Filleron T, Asselain B, Baehner FL, Fumoleau P, Lacroix-Triki M, Anderson JM, Yoshizawa C, Cherbavaz DB, Shak S, Roca L, Sagan C, Lemonnier J, Martin AL, Roché H Tags: BMC Cancer Source Type: research

The unexpected impact of expressive writing on posttraumatic stress and growth in Chinese American breast cancer survivors.
CONCLUSIONS: These findings speak to the importance of examining whether interventions are equally efficacious in different cultures. PMID: 29727480 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - May 4, 2018 Category: Cancer & Oncology Authors: Gallagher MW, Long LJ, Tsai W, Stanton AL, Lu Q Tags: J Clin Psychol Source Type: research

Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery.
CONCLUSIONS: Our results suggest that macrophage phenotype in tumor cells results in radioresistance in breast cancer and shorter DFS after radiotherapy. PMID: 29725763 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - May 3, 2018 Category: Cancer & Oncology Authors: Garvin S, Oda H, Arnesson LG, Lindström A, Shabo I Tags: J Cancer Res Clin Oncol Source Type: research

Cardiac autonomic modulation impairments in advanced breast cancer patients.
CONCLUSIONS: Heart rate variability seems to be a promising, non-invasive tool for early diagnosis of autonomic dysfunction in breast cancer and detection of cardiovascular impairments at cancer diagnosis. Cardiac autonomic modulation is inversely associated with breast cancer staging. PMID: 29721647 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - May 2, 2018 Category: Cancer & Oncology Authors: Arab C, Vanderlei LCM, da Silva Paiva L, Fulghum KL, Fristachi CE, Nazario ACP, Elias S, Gebrim LH, Ferreira Filho C, Gidron Y, Ferreira C Tags: Clin Res Cardiol Source Type: research

Breast MR Imaging: Atlas of Anatomy, Physiology, Pathophysiology, and Breast Imaging Reporting and Data Systems Lexicon.
Abstract The latest edition of the Breast Imaging Reporting and Data Systems lexicon, copyrighted in 2013, contains several changes to the breast MR imaging section. Most changes were implemented to standardize descriptors across breast imaging modalities. New sections on special topics and implant evaluation are included. We review basic MR imaging breast anatomy and a detailed pictorial review of the Breast Imaging Reporting and Data Systems lexicon, including these new sections. In each section we discuss which descriptors are more concerning for malignancy and information radiologists can use to better categor...
Source: Clinical Genitourinary Cancer - April 8, 2018 Category: Cancer & Oncology Authors: Martaindale SR Tags: Magn Reson Imaging Clin N Am Source Type: research

Role of MR Imaging for the Locoregional Staging of Breast Cancer.
Abstract Breast MR imaging has been shown to identify unsuspected sites of cancer in the ipsilateral breast in 16% of women with newly diagnosed breast cancer. Breast MR imaging identifies occult cancer in the contralateral breast in 3% to 5% of women. Early evidence suggests that the added value of MR imaging for staging may be attenuated in women who also undergo tomosynthesis, particularly those with nondense breasts. Breast MR imaging is complementary to ultrasound imaging in evaluating regional nodal basins. Ongoing prospective randomized clinical trials should clarify the impact of preoperative breast MR ima...
Source: Clinical Genitourinary Cancer - April 8, 2018 Category: Cancer & Oncology Authors: Ray KM, Hayward JH, Joe BN Tags: Magn Reson Imaging Clin N Am Source Type: research

Role of MR Imaging in Neoadjuvant Therapy Monitoring.
Abstract Neoadjuvant chemotherapy (NAC) has become an important treatment approach for stage II/III breast cancers to downsize tumor and enable breast-conserving surgery for patients that may otherwise undergo mastectomy. MR imaging has the potential to identify early response or disease progression, enabling potential modification to NAC regimens. Detection of size and morphologic changes is better appreciated with MR imaging than other modalities and is different between molecular subtypes of breast cancer. The combination of DCE-MR imaging and DWI provides the highest sensitivity and specificity. Other new moda...
Source: Clinical Genitourinary Cancer - April 8, 2018 Category: Cancer & Oncology Authors: Le-Petross HT, Lim B Tags: Magn Reson Imaging Clin N Am Source Type: research

Problem-Solving MR Imaging for Equivocal Imaging Findings and Indeterminate Clinical Symptoms of the Breast.
Abstract Breast MR imaging is commonly used for high-risk screening and for assessing the extent of disease in patients with newly diagnosed breast cancer, but its utility for assessing suspicious symptoms and equivocal imaging findings is less widely accepted. The authors review current literature and guidelines regarding the use of breast MR imaging for these indications. Overall, problem-solving breast MR imaging is best reserved for pathologic nipple discharge and sonographically occult architectural distortion with limited biopsy options. Further study is necessary to define the role of problem-solving MR ima...
Source: Clinical Genitourinary Cancer - April 8, 2018 Category: Cancer & Oncology Authors: Cohen E, Leung JWT Tags: Magn Reson Imaging Clin N Am Source Type: research

MR Imaging-Guided Breast Interventions: Indications, Key Principles, and Imaging-Pathology Correlation.
Abstract MR imaging is now routinely performed for breast cancer screening and staging. For suspicious MR imaging-detected lesions that are mammographically and sonographically occult, MR imaging-guided breast interventions, including biopsy, clip placement, and preoperative needle localization, have been developed to permit accurate tissue diagnosis and aid in surgical planning. These procedures are safe, accurate, and effective when performed according to key principles, including proper patient selection, use of appropriate technique, adequate preprocedure preparation and postprocedure patient care, and postpro...
Source: Clinical Genitourinary Cancer - April 8, 2018 Category: Cancer & Oncology Authors: Santiago L, Candelaria RP, Huang ML Tags: Magn Reson Imaging Clin N Am Source Type: research

Developments in Breast Imaging: Update on New and Evolving MR Imaging and Molecular Imaging Techniques.
This article reviews new developments in breast imaging. There is growing interest in creating a shorter, less expensive MR protocol with broader applicability. There is an increasing focus on and consideration for the additive impact that functional analysis of breast pathology have on identifying and characterizing lesions. These developments apply to MR imaging and molecular imaging. This article reviews evolving breast imaging techniques with attention to strengths, weaknesses, and applications of these approaches. We aim to give the reader familiarity with the state of current developments in the field and to increase...
Source: Clinical Genitourinary Cancer - April 8, 2018 Category: Cancer & Oncology Authors: Heller SL, Heacock L, Moy L Tags: Magn Reson Imaging Clin N Am Source Type: research

Comparison of Contrast-Enhanced Mammography and Contrast-Enhanced Breast  MR Imaging.
Comparison of Contrast-Enhanced Mammography and Contrast-Enhanced Breast MR Imaging. Magn Reson Imaging Clin N Am. 2018 May;26(2):259-263 Authors: Lewin J Abstract Contrast-enhanced mammography (CEM) is a contrast-enhanced modality for breast cancer detection that utilizes iodinated contrast and dual-energy imaging performed on a digital mammography unit with only slight modifications. It is approved by the US Food and Drug Administration, commercially available, and in routine clinical use at centers around the world. It has similar sensitivity and specificity to MR Imaging and has advantages in...
Source: Clinical Genitourinary Cancer - April 8, 2018 Category: Cancer & Oncology Authors: Lewin J Tags: Magn Reson Imaging Clin N Am Source Type: research

Use of Breast-Specific PET Scanners and Comparison with MR Imaging.
Abstract The goals of this article are to discuss the role of breast-specific PET imaging of women with breast cancer, compare the clinical performance of positron emission mammography (PEM) and MR imaging for current indications, and provide recommendations for when women should undergo PEM instead of breast MR imaging. PMID: 29622131 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 8, 2018 Category: Cancer & Oncology Authors: Narayanan D, Berg WA Tags: Magn Reson Imaging Clin N Am Source Type: research

Comparison of Breast MR Imaging with Molecular Breast Imaging in Breast Cancer Screening, Diagnosis, Staging, and Treatment Response Evaluation.
This article discusses clinical applications of breast MR imaging and MBI, and compares the performance of these techniques in breast cancer screening, diagnosis, staging, and treatment response evaluation. PMID: 29622132 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 8, 2018 Category: Cancer & Oncology Authors: Rauch GM, Adrada BE Tags: Magn Reson Imaging Clin N Am Source Type: research

How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Surgical Oncologist.
Abstract MR imaging is now readily available for surgeons to incorporate into their practice, thus, begging the question, is this new modality clinically useful? Current literature and expert opinion are reviewed concerning the implementation of breast MR imaging to clinical management of breast cancer. Although breast MR imaging is acknowledged to be highly sensitive in detection of breast cancer, its routine application to surgical practice remains controversial because these gains in sensitivity have not been demonstrated to translate into improved long-term patient outcomes. Current clinical trials and the fut...
Source: Clinical Genitourinary Cancer - April 8, 2018 Category: Cancer & Oncology Authors: Raber B, Bea VJ, Bedrosian I Tags: Magn Reson Imaging Clin N Am Source Type: research

How Does MR Imaging Help Care for the Breast Cancer Patient? Perspective of a Medical Oncologist.
This article reviews the impact of MR imaging in different settings on medical oncology decision-making in patients with breast cancer. PMID: 29622134 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 8, 2018 Category: Cancer & Oncology Authors: Raghavendra AS, Tripathy D Tags: Magn Reson Imaging Clin N Am Source Type: research

How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Radiation Oncologist.
Abstract Radiation therapy is used in many cases of both early and late breast cancer. The authors examine the role of MR imaging as it pertains to radiotherapy planning and treatment approaches for patients with breast cancer. MR imaging can assist the radiation oncologist in determining the best radiation approach and in creating treatment planning volumes. MR imaging may be useful in the setting of accelerated partial breast irradiation. Radiation oncologists should attend to MR breast images, when obtained, to ensure that these imaging findings are taken into consideration when developing a radiation therapy p...
Source: Clinical Genitourinary Cancer - April 8, 2018 Category: Cancer & Oncology Authors: Christopherson KM, Smith BD Tags: Magn Reson Imaging Clin N Am Source Type: research

Breast MR Imaging in Era of Value-Based Medicine.
PMID: 29622138 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 8, 2018 Category: Cancer & Oncology Authors: Leung JWT Tags: Magn Reson Imaging Clin N Am Source Type: research

Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.
CONCLUSION: The incidence of STIC after RRSO in BRCA mutation carriers is low (0.8%) and it presents an excellent oncological outcome. Patients after RRSO, however, run the risk to develop other types of cancer during follow-up and should be properly advised before the prophylactic surgery. PMID: 29623583 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 5, 2018 Category: Cancer & Oncology Authors: Minig L, Cabrera S, Oliver R, Couso A, Rubio MJ, Iacoponi S, Martin-Salamanca MB, Carballo-Rastrilla S, Cádenas-Rebollo JM, García-Garcia A, Gil-Ibáñez B, Juan-Fita MJ, Patrono MG Tags: Clin Transl Oncol Source Type: research

Lipid accumulation in human breast cancer cells injured by iron depletors.
CONCLUSIONS: Iron starvation induces a hypoxia-like program able to scavenge nutrients from the extracellular environment, and cells assume a hypertrophic phenotype. Such survival strategy is accompanied by the ER-dependent massive cytoplasmic vacuolization, mitochondrial dysfunctions, and LD accumulation and then evolves into cell death. LDs containing a greater proportion of unsaturated lipids are released as a consequence of cell death. The consequence of the disruption of iron metabolism in tumour tissue and the effects of LDs on intercellular communication, cancer-inflammation axis, and immunity remain to be explored....
Source: Clinical Genitourinary Cancer - April 3, 2018 Category: Cancer & Oncology Authors: De Bortoli M, Taverna E, Maffioli E, Casalini P, Crisafi F, Kumar V, Caccia C, Polli D, Tedeschi G, Bongarzone I Tags: J Exp Clin Cancer Res Source Type: research

Knowledge and practices on healthy eating among breast cancer patients on chemotherapy.
PMID: 29616947 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 1, 2018 Category: Cancer & Oncology Authors: Bali G, Kyprianidou A, Dardavessis T, Theodoridis X, Matthaiou A, Anogeianaki A, Ainali A, Botsolis K, Vagionas A, Stoltidis D, Makrantonakis P, Andreadis C, Tirodimos I, Grammatikopoulou MG, Chourdakis M Tags: Clin Nutr ESPEN Source Type: research

Squamous cell carcinoma of the breast as a clinical diagnostic challenge.
Abstract Squamous cell carcinoma (SqCC) of the breast should be differentiated between the primary skin keratinizing squamous carcinoma and squamous metaplastic cancer. In the current study, the cases of two patients who were diagnosed with SqCC originated from skin and the breast were discussed. A fine-needle aspiration biopsy confirmed the presence of atypical squamous cells. In both cases, the microscopic examination of the surgical specimen revealed a malignant neoplasm differentiated into SqCC characterized by keratinizing cancer cells with abundant eosiphilic cytoplasm with large, hyperchromatic vesicular nu...
Source: Clinical Genitourinary Cancer - March 22, 2018 Category: Cancer & Oncology Authors: Jakubowska K, Kańczuga-Koda L, Kisielewski W, Koda M, Famulski W Tags: Mol Clin Oncol Source Type: research

Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment.
Conclusion: Denosumab significantly increased L-BMD and H-BMD to comparable degrees in both groups; therefore, it represents a good therapeutic option for OP receiving breast cancer treatment as well as primary OP. Also, vitamin D supplementation is required due to the potential hypocalcemia, and estrogen may be responsible for the decrease of serum calcium in the breast cancer patients. PMID: 29559791 [PubMed] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 22, 2018 Category: Cancer & Oncology Authors: Nakamura Y, Kamimura M, Morikawa A, Taguchi A, Suzuki T, Kato H Tags: Ther Clin Risk Manag Source Type: research

Breast cancer: Changes in clonal dynamics predict response to palbociclib.
PMID: 29557393 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 20, 2018 Category: Cancer & Oncology Authors: Sidaway P Tags: Nat Rev Clin Oncol Source Type: research

Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.
Abstract Purpose Locoregional control for inflammatory breast cancers and chest wall recurrences is suboptimal, which has motivated interest in radiosensitization to intensify therapy. Preclinical studies have suggested a favorable therapeutic index when poly (ADP-ribose) polymerase inhibitors are used as radiosensitizers; clinical investigation is necessary to establish appropriate dosing and confirm safety. Patients and Methods We conducted a multi-institutional phase I study of veliparib and concurrent radiotherapy (RT) to the chest wall and regional lymph nodes in 30 patients with inflammatory or locally recur...
Source: Clinical Genitourinary Cancer - March 20, 2018 Category: Cancer & Oncology Authors: Jagsi R, Griffith KA, Bellon JR, Woodward WA, Horton JK, Ho A, Feng FY, Speers C, Overmoyer B, Sabel M, Schott AF, Pierce L, Translational Breast Cancer Research Consortium Tags: J Clin Oncol Source Type: research

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor ‒Positive/Human Epidermal Growth Factor Receptor 2‒Negative Advanced Breast Cancer.
CONCLUSIONS: Pembrolizumab was well-tolerated with modest but durable objective response in certain patients with previously treated, advanced, PD-L1‒positive, ER+/HER2- breast cancer. PMID: 29559561 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 20, 2018 Category: Cancer & Oncology Authors: Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachev J, Le Tourneau C, van Brummelen EMJ, Varga A, Salgado R, Loi S, Saraf S, Pietrangelo D, Karantza V, Tan AR Tags: Clin Cancer Res Source Type: research

Targeting bromodomain and extra-terminal (BET) family proteins in castration resistant prostate cancer (CRPC).
, Swain A, de Bono JS Abstract PURPOSE:  Persistent androgen receptor (AR) signaling drives castration resistant prostate cancer (CRPC) and confers resistance to AR targeting therapies. Novel therapeutic strategies to overcome this are urgently required. We evaluated how bromodomain and extra-terminal (BET) protein inhibitors (BETi) abrogate aberrant AR signaling in CRPC. EXPERIMENTAL DESIGN:  We determined associations between BET expression, AR driven transcription and patient outcome; and the effect and mechanism by which chemical BETi (JQ1 and GSK1210151A; I-BET151) and BET family protein knockd...
Source: Clinical Genitourinary Cancer - March 19, 2018 Category: Cancer & Oncology Authors: Welti J, Sharp A, Yuan W, Dolling DI, Nava Rodrigues D, Figueiredo I, Gil V, Neeb A, Clarke M, Seed G, Crespo M, Sumanasuriya S, Ning J, Knight E, Francis JC, Hughes A, Halsey WS, Paschalis A, Mani RS, Raj GV, Plymate S, Carreira S, Boysen G, Chinnaiyan A Tags: Clin Cancer Res Source Type: research

Triple-negative breast cancers - a panoply of cancer types.
PMID: 29555966 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 19, 2018 Category: Cancer & Oncology Authors: Pareja F, Reis-Filho JS Tags: Nat Rev Clin Oncol Source Type: research

Clinicopathological features of metaplastic breast carcinoma.
CONCLUSIONS: Metaplastic carcinoma of the breast is relatively rare and, in our series, its incidence was 0.6%. According to its immunohistochemical characteristics, MpBC can be interpreted as a subgroup of triplenegative breast cancers (TNBC). Five of the presented patients resembled the subgroup of TNBC with a basaloid phenotype. The chemotherapy regimens suggested in the treatment of MpBC are platin in the epithelial subgroup and high-dose anthracycline in the mesenchymal subgroup. There is a need of new studies that evaluate different choices of treatment as MpBC has a bad prognosis and an aggressive nature. PMID:...
Source: Clinical Genitourinary Cancer - March 19, 2018 Category: Cancer & Oncology Authors: Hasdemir OA, Tokgöz S, Köybaşıoğlu F, Karabacak H, Yücesoy C, İmamoğlu Gİ Tags: Adv Clin Exp Med Source Type: research

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equil...
Source: Clinical Genitourinary Cancer - March 17, 2018 Category: Cancer & Oncology Authors: Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA Tags: J Clin Endocrinol Metab Source Type: research

Coexisting genomic aberrations associated with lymph node metastasis in breast cancer.
HJ Abstract Single cancer cell sequencing studies currently use randomly-selected cells, limiting correlations between genomic aberrations, morphology and spatial localization. We laser-captured microdissected single cells from morphologically-distinct areas of primary breast cancer and corresponding lymph node metastasis and performed whole-exome or deep-target sequencing of greater than 100 such cells. Two major subclones co-existed in different areas of the primary tumor, and the lymph node metastasis originated from a minor subclone in the invasive front of the primary tumor with additional copy number change...
Source: Clinical Genitourinary Cancer - March 15, 2018 Category: Cancer & Oncology Authors: Bao L, Qian Z, Lyng MB, Wang L, Yu Y, Wang T, Zhang X, Yang H, Brünner N, Wang J, Ditzel HJ Tags: J Clin Invest Source Type: research

Sterilized talc pleurodesis for malignant pleural effusions: a Phase II study for investigational new drug application in Japan.
Conclusion: The efficacy and safety of NPC-05 for malignant pleural effusion in Japanese patients was verified, and the clinical outcomes with talc were confirmed to be the same as previously reported in other countries. There is thought to be a high level of need for this agent in the treatment of malignant pleural effusion in Japan. PMID: 29528450 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 8, 2018 Category: Cancer & Oncology Authors: Saka H, Oki M, Kitagawa C, Kogure Y, Kojima Y, Saito AM, Ishida A, Miyazawa T, Takeda K, Nakagawa K, Sasada S, Negoro S Tags: Jpn J Clin Oncol Source Type: research

A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
CONCLUSION: In Japanese MBC patients in a real-world setting, eribulin showed a survival benefit and tolerability similar to that in previous reports. PMID: 29498210 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 1, 2018 Category: Cancer & Oncology Authors: Kikuchi Y, Uchida Y, Shirakawa K, Kanauchi H, Niwa T, Nishioka K, Tada K, Hashimoto M, Yasuda H, Sugiura R, Kawabata H, Seto Y, Ogawa T Tags: Asia Pac J Clin Oncol Source Type: research

Alleviation of Side Effects and Distress in Breast Cancer Patients by Cognitive-Behavioral Interventions: A Systematic Review and Meta-analysis.
Abstract Cognitive and behavioral interventions (CBI) have been used for breast cancer patients with various stages of the disease or undergoing different treatments. However, no quantitative review has summarized their efficacy on the side effects of treatment, distress, and quality of life in the acute treatment setting after diagnosis. This meta-analysis synthesizes data from 19 randomized clinical trials in order to: (a) provide an estimation of overall effect of CBI in breast cancer patients during treatment for breast cancer, i.e., neo-adjuvant and adjuvant treatment; (b) provide average effect sizes on side...
Source: Clinical Genitourinary Cancer - February 26, 2018 Category: Cancer & Oncology Authors: Cobeanu O, David D Tags: J Clin Psychol Med Settings Source Type: research

Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes.
n J, Bergh J Abstract Metastatic breast cancers are still incurable. Characterizing the evolutionary landscape of these cancers, including the role of metastatic axillary lymph nodes (ALNs) in seeding distant organ metastasis, can provide a rational basis for effective treatments. Here, we have described the genomic analyses of the primary tumors and metastatic lesions from 99 samples obtained from 20 patients with breast cancer. Our evolutionary analyses revealed diverse spreading and seeding patterns that govern tumor progression. Although linear evolution to successive metastatic sites was common, parallel evol...
Source: Clinical Genitourinary Cancer - February 26, 2018 Category: Cancer & Oncology Authors: Ullah I, Karthik GM, Alkodsi A, Kjällquist U, Stålhammar G, Lövrot J, Martinez NF, Lagergren J, Hautaniemi S, Hartman J, Bergh J Tags: J Clin Invest Source Type: research

Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer.
BA, Putluri N, Sicheri F, Rosen JM, Lewis MT, Chen X Abstract The unfolded protein response (UPR) is a cellular homeostatic mechanism that is activated in many human cancers and plays pivotal roles in tumor progression and therapy resistance. However, the molecular mechanisms for UPR activation and regulation in cancer cells remain elusive. Here, we show that oncogenic MYC regulates the inositol-requiring enzyme 1 (IRE1)/X-box binding protein 1 (XBP1) branch of the UPR in breast cancer via multiple mechanisms. We found that MYC directly controls IRE1 transcription by binding to its promoter and enhancer. Furthermo...
Source: Clinical Genitourinary Cancer - February 26, 2018 Category: Cancer & Oncology Authors: Zhao N, Cao J, Xu L, Tang Q, Dobrolecki LE, Lv X, Talukdar M, Lu Y, Wang X, Hu DZ, Shi Q, Xiang Y, Wang Y, Liu X, Bu W, Jiang Y, Li M, Gong Y, Sun Z, Ying H, Yuan B, Lin X, Feng XH, Hartig SM, Li F, Shen H, Chen Y, Han L, Zeng Q, Patterson JB, Kaipparettu Tags: J Clin Invest Source Type: research

Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer.
Abstract Breast cancer metastasis remains a clinical challenge, even within a single patient across multiple sites of the disease. Genome-wide comparisons of both the DNA and gene expression of primary tumors and metastases in multiple patients could help elucidate the underlying mechanisms that cause breast cancer metastasis. To address this issue, we performed DNA exome and RNA sequencing of matched primary tumors and multiple metastases from 16 patients, totaling 83 distinct specimens. We identified tumor-specific drivers by integrating known protein-protein network information with RNA expression and somatic D...
Source: Clinical Genitourinary Cancer - February 26, 2018 Category: Cancer & Oncology Authors: Siegel MB, He X, Hoadley KA, Hoyle A, Pearce JB, Garrett AL, Kumar S, Moylan VJ, Brady CM, Van Swearingen AE, Marron D, Gupta GP, Thorne LB, Kieran N, Livasy C, Mardis ER, Parker JS, Chen M, Anders CK, Carey LA, Perou CM Tags: J Clin Invest Source Type: research

Integrated Multi-Omic Analyses Support Distinguishing Secretory Carcinoma of the Breast from Basal-Like Triple-Negative Breast Cancer.
CONCLUSION AND CLINICAL RELEVANCE: Our multi-omic analyses provide evidence that SC harbours substantially different molecular genomic and proteomic landscapes compared with BL-TNBC. These results provide an entire spectrum of in-depth molecular landscapes to support the hypothesis that SC is distinct from BL-TNBC. This article is protected by copyright. All rights reserved. PMID: 29476606 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - February 24, 2018 Category: Cancer & Oncology Authors: Jin MS, Lee H, Woo J, Choi S, Do MS, Kim K, Song MJ, Kim Y, Park IA, Han D, Ryu HS Tags: Proteomics Clin Appl Source Type: research

CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.
Abstract This issue of Clinical Pharmacology & Therapeutics (CPT) includes the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for using CYP2D6 genotyping to guide tamoxifen therapy for breast cancer patients. CYP2D6 metabolizes tamoxifen to its more active metabolite, endoxifen, and patients with reduced CYP2D6 activity have reduced circulating endoxifen concentrations. In this associated commentary, we recognize and honor the late Dr. David Flockhart, who began the research and made early fundamental discoveries on tamoxifen that have now resulted in this guideline. PMID: 29473149 [...
Source: Clinical Genitourinary Cancer - February 23, 2018 Category: Cancer & Oncology Authors: Skaar TC, Desta Z Tags: Clin Pharmacol Ther Source Type: research

Focal Irradiation And Systemic Transforming Growth Factor β Blockade in Metastatic Breast Cancer.
CONCLUSIONS: TGFβ blockade during radiotherapy was feasible and well tolerated. Patients receiving the higher fresolimumab dose had a favorable systemic immune response and experienced longer median overall survival than the lower dose group. PMID: 29476019 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - February 23, 2018 Category: Cancer & Oncology Authors: Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie M, Ratikan J, Felix C, Hwang L, Faull K, Sayre JW, Hurvitz S, Glaspy J, Comin-Anduix B, Demaria S, Schaue D, McBride WH Tags: Clin Cancer Res Source Type: research

Merging perspectives: genotype-directed molecular therapy for hereditary diffuse gastric cancer (HDGC) and E-cadherin-EGFR crosstalk.
Abstract Hereditary diffuse gastric cancer is a cancer predisposition syndrome associated with germline mutations of the E-cadherin gene (CDH1; NM_004360). Male CDH1 germline mutation carriers have by the age of 80 years an estimated 70% cumulative incidence of gastric cancer, females of 56% for gastric and of 42% for lobular breast cancer. Metastatic HDGC has a poor prognosis which is worse than for sporadic gastric cancer. To date, there have been no treatment options described tailored to this molecular subtype of gastric cancer. Here we review recent differential drug screening and gene expression results...
Source: Clinical Genitourinary Cancer - February 22, 2018 Category: Cancer & Oncology Authors: Li D, Lo W, Rudloff U Tags: Clin Transl Med Source Type: research

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
E, Bachelot T, Wang Q, Perez-Tenorio G, Can de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S Abstract Purpose Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA) mutations are frequently observed in primary breast cancer. We evaluated their prognostic relevance by performing a pooled analysis of individual patient data. Patients and Methods Associations between PIK3CA status and clinicopathologic characteristics were tested by applying Cox regression models adjusted for age, tumor size, nodes, grade, estrogen receptor (ER) status, human epidermal growth fact...
Source: Clinical Genitourinary Cancer - February 22, 2018 Category: Cancer & Oncology Authors: Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, O'Toole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA, Lerma Tags: J Clin Oncol Source Type: research

Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?
Society of Medical Oncology (SEOM) Abstract The association between venous thromboembolism (VTE) and cancer has been recognized for more than 100 years. Numerous studies have been performed to investigate strategies to decrease VTE incidence and to establish whether treating VTE impacts cancer progression and overall survival. Accordingly, it is important to understand the role of the hemostatic system in tumorigenesis and progression, as there is abundant evidence associating it with cell survival and proliferation, tumor angiogenesis, invasion, and dissemination, and metastasis formation. In attempts to fu...
Source: Clinical Genitourinary Cancer - February 22, 2018 Category: Cancer & Oncology Authors: García-Escobar I, Beato-Zambrano C, Muñoz Langa J, Brozos Vázquez E, Obispo Portero B, Gutiérrez-Abad D, Muñoz Martín AJ, Cancer and Thrombosis Working Group of the Spanish Society of Medical Oncology (SEOM) Tags: Clin Transl Oncol Source Type: research

The Role of Optimism, Social Constraints, Coping, and Cognitive Processing in Psychosocial Adjustment Among Breast Cancer Survivors.
Abstract The social-cognitive processing model suggests that a socially constrained environment may impede adjustment to a chronic illness. The present study primarily investigated the mediating psychological pathways through which social constraints on cancer-related disclosure, low optimism, disengagement-oriented coping, and brooding could be associated with low levels of psychosocial adjustment. One hundred twenty-five female breast cancer survivors participated in a cross-sectional study. Path analysis was used to examine the proposed model. Low optimism, increased social constraints, and higher levels of bro...
Source: Clinical Genitourinary Cancer - February 21, 2018 Category: Cancer & Oncology Authors: Kolokotroni P, Anagnostopoulos F, Hantzi A Tags: J Clin Psychol Med Settings Source Type: research

Cognitive Behavior Therapy for Fear of Cancer Recurrence: A Case Study.
Abstract This case study describes the course and content of cognitive behavior therapy (CBT) for clinical fear of cancer recurrence (FCR) in a breast cancer survivor. The CBT for clinical FCR consisted of seven face-to-face therapy sessions and one telephone session. The primary treatment goal was to reduce FCR severity by modifying cognitive processes and dysfunctional behavior. Assessments of FCR and quality of life were completed by the breast cancer survivor pre-therapy, post-therapy, and at 6 and 12 months of post-therapy. In each treatment session, perceived control over FCR was assessed. A clinical nurse s...
Source: Clinical Genitourinary Cancer - February 21, 2018 Category: Cancer & Oncology Authors: van de Wal M, Servaes P, Berry R, Thewes B, Prins J Tags: J Clin Psychol Med Settings Source Type: research

Serum levels of testosterone and SHBG in association with body mass index improve the predictive capability of consolidate tumor biomarkers in pre- and postmenopausal breast cancer patients.
Conclusions: Patient-associated features such as BMI and serum levels of TS and SHBG can improve the predictive capability of consolidate tumor-specific biomarkers in both pre- and postmenopause, thus providing a relevant contribution to the decision-making process. PMID: 29474646 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - February 21, 2018 Category: Cancer & Oncology Authors: Coradini D, Orenti A, Venturelli E, Cavalleri A, Biganzoli E, Oriana S Tags: Jpn J Clin Oncol Source Type: research

Cancer survivors: An expanding population with an increased cardiometabolic risk.
Abstract In the last decades the survival rate of patients diagnosed with cancer - both in childhood and adulthood - significantly improved, leading to a growing number of cancer survivors (CS) within general population. Despite the better survival rate related to the cancer diagnosis, CS show increased mortality and morbidity if compared to non-cancer population, due to the occurrence of health conditions categorized as late effects of previous anticancer treatments. Cardiovascular (CV) diseases are one of the main responsible for this increased morbidity of CS. Besides the direct injury that both chemotherapy an...
Source: Clinical Genitourinary Cancer - February 20, 2018 Category: Cancer & Oncology Authors: Felicetti F, Fortunati N, Brignardello E Tags: Diabetes Res Clin Pract Source Type: research